N Horikoshi

2.4k total citations
82 papers, 2.0k citations indexed

About

N Horikoshi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, N Horikoshi has authored 82 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in N Horikoshi's work include Cancer Treatment and Pharmacology (43 papers), Colorectal Cancer Treatments and Studies (19 papers) and Neutropenia and Cancer Infections (14 papers). N Horikoshi is often cited by papers focused on Cancer Treatment and Pharmacology (43 papers), Colorectal Cancer Treatments and Studies (19 papers) and Neutropenia and Cancer Infections (14 papers). N Horikoshi collaborates with scholars based in Japan, United States and Greece. N Horikoshi's co-authors include T Taguchi, Yasushi Mitachi, Yuh Sakata, Atsushi Ohtsu, K Sugimachi, Hideo Baba, Victorio Rodriguez, Gerald P. Bodey, Yoshihiko Maehara and Keizō Sugimachi and has published in prestigious journals such as Cancer, Antimicrobial Agents and Chemotherapy and British Journal of Cancer.

In The Last Decade

N Horikoshi

80 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N Horikoshi Japan 18 1.4k 1.0k 380 303 220 82 2.0k
James J. Mezhir United States 26 748 0.5× 798 0.8× 831 2.2× 309 1.0× 212 1.0× 52 2.1k
Hideo Baba Japan 26 1.0k 0.7× 657 0.6× 712 1.9× 370 1.2× 175 0.8× 118 2.1k
Mitsukuni Suenaga Japan 21 1.1k 0.8× 533 0.5× 240 0.6× 271 0.9× 121 0.6× 149 1.5k
L Domellöf Sweden 21 1.3k 0.9× 604 0.6× 1.7k 4.4× 347 1.1× 186 0.8× 80 2.6k
Makoto Iwahashi Japan 27 801 0.6× 862 0.8× 825 2.2× 530 1.7× 365 1.7× 128 2.3k
Sameh Mikhail United States 22 747 0.5× 415 0.4× 376 1.0× 270 0.9× 117 0.5× 70 1.5k
Hye Seung Han South Korea 27 683 0.5× 734 0.7× 766 2.0× 596 2.0× 201 0.9× 107 2.3k
H. G. Beger Germany 24 1.9k 1.3× 615 0.6× 1.1k 2.8× 604 2.0× 86 0.4× 56 2.7k
Jieer Ying China 18 850 0.6× 532 0.5× 430 1.1× 324 1.1× 126 0.6× 95 1.7k
Xiaxing Deng China 26 1.4k 1.0× 800 0.8× 1.0k 2.7× 324 1.1× 118 0.5× 116 2.1k

Countries citing papers authored by N Horikoshi

Since Specialization
Citations

This map shows the geographic impact of N Horikoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Horikoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Horikoshi more than expected).

Fields of papers citing papers by N Horikoshi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Horikoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Horikoshi. The network helps show where N Horikoshi may publish in the future.

Co-authorship network of co-authors of N Horikoshi

This figure shows the co-authorship network connecting the top 25 collaborators of N Horikoshi. A scholar is included among the top collaborators of N Horikoshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Horikoshi. N Horikoshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kusama, M., Tadashi Nomizu, Kenjiro Aogi, et al.. (2009). Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer. 17(4). 233–240. 17 indexed citations
2.
Sawaki, Masataka, Yoshinori Ito, Futoshi Akiyama, et al.. (2006). High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer. 13(2). 172–178. 47 indexed citations
3.
Shirao, Kuniaki, Atsushi Ohtsu, Hideho Takada, et al.. (2004). Phase II study of oral S‐1 for treatment of metastatic colorectal carcinoma. Cancer. 100(11). 2355–2361. 101 indexed citations
4.
Saeki, Toshiaki, Kenji Eguchi, Takahiko Sugiura, et al.. (2004). Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors. Cancer Chemotherapy and Pharmacology. 54(5). 459–468. 2 indexed citations
5.
Aihara, Tomohiko, Yuichi Takatsuka, Kuniaki Itoh, et al.. (2003). Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer. Oncology. 64(2). 124–130. 10 indexed citations
6.
Tada, Keiichiro, Yoshinori Ito, Kiyohiko Hatake, et al.. (2003). Severe infusion reaction induced by trastuzumab: A case report. Breast Cancer. 10(2). 167–169. 9 indexed citations
7.
Yamaguchi, Kensei, Masahiro Tada, N Horikoshi, et al.. (2002). Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 5(2). 90–95. 83 indexed citations
8.
Kobayashi, Kunihiko, M. Fukuoka, Kenji Takeuchi, et al.. (2002). Phase I studies of nogitecan hydrochloride for Japanese. International Journal of Clinical Oncology. 7(3). 177–186. 7 indexed citations
9.
Fujiwara, Keiichi, Takashi Saotome, Nobuyuki Mizunuma, et al.. (2002). Irinotecan hydrochloride for the treatment of recurrent and refractory non‐Hodgkin lymphoma. Cancer. 94(3). 594–600. 12 indexed citations
10.
Sugimachi, Keizō, Yoshihiko Maehara, N Horikoshi, et al.. (1999). An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers. Oncology. 57(3). 202–210. 150 indexed citations
11.
Kurihara, Minoru, N Horikoshi, Nobuteru Kikkawa, et al.. (1999). Phase II study of raltitrexed (Tomudex®) in chemotherapy-pretreated patients with advanced colorectal cancer. Anti-Cancer Drugs. 10(8). 741–748. 9 indexed citations
12.
Ito, Yoshinori, Taketo Mukaiyama, Makoto Ogawa, et al.. (1999). Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up. Cancer Chemotherapy and Pharmacology. 43(1). 8–12. 2 indexed citations
13.
Ito, Yoshinori, N Horikoshi, Toru Watanabe, et al.. (1998). Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. Investigational New Drugs. 16(2). 183–190. 15 indexed citations
14.
Sakata, Yuh, Atsushi Ohtsu, N Horikoshi, et al.. (1998). Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients. European Journal of Cancer. 34(11). 1715–1720. 499 indexed citations
15.
Tsukagoshi, Shigeru, N Horikoshi, Shunji Takahashi, et al.. (1996). A novel transdermal preparation of morphine and possibility of the clinical application for cancer pain.. Drug Delivery System. 11(6). 393–397. 1 indexed citations
16.
Adachi, I, Toru Watanabe, S Takashima, et al.. (1996). A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. British Journal of Cancer. 73(2). 210–216. 78 indexed citations
17.
Inoue, Keiichi, et al.. (1992). [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].. PubMed. 19(4). 477–82. 3 indexed citations
18.
Inoue, Katsuhiro, Makoto Ogawa, N Horikoshi, et al.. (1989). Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Investigational New Drugs. 7(2-3). 213–218. 16 indexed citations
19.
Ogawa, Makoto, N Horikoshi, Katsuhiro Inoue, et al.. (1987). [A phase I study of carboplatin].. PubMed. 14(5 Pt 1). 1292–6. 5 indexed citations
20.
Fujimoto, Shuichi, et al.. (1977). Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.. PubMed. 68(5). 543–52. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James J. Mezhir Breakdown of academic impact, for papers by Hideo Baba Breakdown of academic impact, for papers by Mitsukuni Suenaga Breakdown of academic impact, for papers by L Domellöf Breakdown of academic impact, for papers by Makoto Iwahashi Breakdown of academic impact, for papers by Sameh Mikhail Breakdown of academic impact, for papers by Hye Seung Han Breakdown of academic impact, for papers by H. G. Beger Breakdown of academic impact, for papers by Jieer Ying Breakdown of academic impact, for papers by Xiaxing Deng
Rankless by CCL
2026